Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Total Assets : ¥9,786 Mil (As of Jun. 2024)

Nanjing King-Friend Biochemical Pharmaceutical Co Total Assets Chart

Nanjing King-Friend Biochemical Pharmaceutical Co Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Total Assets		Get a 7-Day Free Trial					5,078.42	7,720.36	8,216.89	10,010.10	9,524.26

Nanjing King-Friend Biochemical Pharmaceutical Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Total Assets	Get a 7-Day Free Trial															11,095.25	11,122.72	9,524.26	9,635.05	9,785.83

Nanjing King-Friend Biochemical Pharmaceutical Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Nanjing King-Friend Biochemical Pharmaceutical Co's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Nanjing King-Friend Biochemical Pharmaceutical Co's Total Assets for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing King-Friend Biochemical Pharmaceutical Co  (SHSE:603707) Total Assets Explanation

Total Assets is connected with ROA %.

Nanjing King-Friend Biochemical Pharmaceutical Co's annualized ROA % for the quarter that ended in Jun. 2024 is

Note: The Net Income data used here is four times the quarterly (Jun. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Nanjing King-Friend Biochemical Pharmaceutical Co's Asset Turnover for the quarter that ended in Jun. 2024 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Nanjing King-Friend Biochemical Pharmaceutical Co Total Assets Related Terms

Thank you for viewing the detailed overview of Nanjing King-Friend Biochemical Pharmaceutical Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanjing King-Friend Biochemical Pharmaceutical Co Business Description